ARBUTUS BIOPHARMA CORP (ABUS) Stock Fundamental Analysis

NASDAQ:ABUS • CA03879J1003

3.98 USD
-0.03 (-0.75%)
At close: Feb 13, 2026
4.083 USD
+0.1 (+2.59%)
After Hours: 2/13/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

ABUS gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 523 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ABUS as it has an excellent financial health rating, but there are worries on the profitability. ABUS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • ABUS had negative earnings in the past year.
  • In the past year ABUS has reported a negative cash flow from operations.
  • ABUS had negative earnings in each of the past 5 years.
  • In the past 5 years ABUS always reported negative operating cash flow.
ABUS Yearly Net Income VS EBIT VS OCF VS FCFABUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

  • ABUS has a Return On Assets of -43.27%. This is comparable to the rest of the industry: ABUS outperforms 56.79% of its industry peers.
  • The Return On Equity of ABUS (-54.62%) is better than 64.63% of its industry peers.
Industry RankSector Rank
ROA -43.27%
ROE -54.62%
ROIC N/A
ROA(3y)-46.36%
ROA(5y)-47.53%
ROE(3y)-63.75%
ROE(5y)-63.56%
ROIC(3y)N/A
ROIC(5y)N/A
ABUS Yearly ROA, ROE, ROICABUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ABUS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABUS Yearly Profit, Operating, Gross MarginsABUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • ABUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ABUS has been increased compared to 1 year ago.
  • ABUS has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for ABUS has been reduced compared to a year ago.
ABUS Yearly Shares OutstandingABUS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
ABUS Yearly Total Debt VS Total AssetsABUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • ABUS has an Altman-Z score of 3.19. This indicates that ABUS is financially healthy and has little risk of bankruptcy at the moment.
  • ABUS has a better Altman-Z score (3.19) than 68.64% of its industry peers.
  • ABUS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.19
ROIC/WACCN/A
WACC12.25%
ABUS Yearly LT Debt VS Equity VS FCFABUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

  • A Current Ratio of 18.80 indicates that ABUS has no problem at all paying its short term obligations.
  • The Current ratio of ABUS (18.80) is better than 95.41% of its industry peers.
  • A Quick Ratio of 18.80 indicates that ABUS has no problem at all paying its short term obligations.
  • ABUS has a better Quick ratio (18.80) than 95.41% of its industry peers.
Industry RankSector Rank
Current Ratio 18.8
Quick Ratio 18.8
ABUS Yearly Current Assets VS Current LiabilitesABUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • ABUS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.24%, which is quite impressive.
  • The Revenue has grown by 116.64% in the past year. This is a very strong growth!
  • ABUS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.53% yearly.
EPS 1Y (TTM)45.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.56%
Revenue 1Y (TTM)116.64%
Revenue growth 3Y-17.5%
Revenue growth 5Y0.53%
Sales Q2Q%-60.49%

3.2 Future

  • ABUS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.05% yearly.
  • The Revenue is expected to grow by 94.81% on average over the next years. This is a very strong growth
EPS Next Y48.31%
EPS Next 2Y24.86%
EPS Next 3Y23.03%
EPS Next 5Y24.05%
Revenue Next Year120.47%
Revenue Next 2Y-59.78%
Revenue Next 3Y12.63%
Revenue Next 5Y94.81%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ABUS Yearly Revenue VS EstimatesABUS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 50M 100M 150M
ABUS Yearly EPS VS EstimatesABUS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • ABUS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ABUS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABUS Price Earnings VS Forward Price EarningsABUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABUS Per share dataABUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

  • ABUS's earnings are expected to grow with 23.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.86%
EPS Next 3Y23.03%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ABUS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ARBUTUS BIOPHARMA CORP

NASDAQ:ABUS (2/13/2026, 8:00:00 PM)

After market: 4.083 +0.1 (+2.59%)

3.98

-0.03 (-0.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)02-26
Inst Owners62.61%
Inst Owner Change-1.85%
Ins Owners0.79%
Ins Owner Change0.23%
Market Cap765.43M
Revenue(TTM)14.61M
Net Income(TTM)-42.28M
Analysts84.44
Price Target5.78 (45.23%)
Short Float %8.69%
Short Ratio9.07
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)47.07%
Min EPS beat(2)-26.5%
Max EPS beat(2)120.64%
EPS beat(4)2
Avg EPS beat(4)21.27%
Min EPS beat(4)-26.5%
Max EPS beat(4)120.64%
EPS beat(8)5
Avg EPS beat(8)11.45%
EPS beat(12)7
Avg EPS beat(12)10.47%
EPS beat(16)11
Avg EPS beat(16)13.19%
Revenue beat(2)1
Avg Revenue beat(2)251.51%
Min Revenue beat(2)-59.06%
Max Revenue beat(2)562.08%
Revenue beat(4)1
Avg Revenue beat(4)124.73%
Min Revenue beat(4)-59.06%
Max Revenue beat(4)562.08%
Revenue beat(8)1
Avg Revenue beat(8)45.63%
Revenue beat(12)2
Avg Revenue beat(12)28.57%
Revenue beat(16)5
Avg Revenue beat(16)37.7%
PT rev (1m)0%
PT rev (3m)7.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-19.66%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.23%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-43.24%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.34%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 52.41
P/FCF N/A
P/OCF N/A
P/B 9.89
P/tB 9.89
EV/EBITDA N/A
EPS(TTM)-0.23
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS0.08
BVpS0.4
TBVpS0.4
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -43.27%
ROE -54.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.36%
ROA(5y)-47.53%
ROE(3y)-63.75%
ROE(5y)-63.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.55%
Cap/Sales 0.59%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 18.8
Quick Ratio 18.8
Altman-Z 3.19
F-Score5
WACC12.25%
ROIC/WACCN/A
Cap/Depr(3y)40.22%
Cap/Depr(5y)35.71%
Cap/Sales(3y)3.27%
Cap/Sales(5y)4.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.56%
EPS Next Y48.31%
EPS Next 2Y24.86%
EPS Next 3Y23.03%
EPS Next 5Y24.05%
Revenue 1Y (TTM)116.64%
Revenue growth 3Y-17.5%
Revenue growth 5Y0.53%
Sales Q2Q%-60.49%
Revenue Next Year120.47%
Revenue Next 2Y-59.78%
Revenue Next 3Y12.63%
Revenue Next 5Y94.81%
EBIT growth 1Y57.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y47.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y47.13%
OCF growth 3YN/A
OCF growth 5YN/A

ARBUTUS BIOPHARMA CORP / ABUS FAQ

What is the ChartMill fundamental rating of ARBUTUS BIOPHARMA CORP (ABUS) stock?

ChartMill assigns a fundamental rating of 4 / 10 to ABUS.


What is the valuation status for ABUS stock?

ChartMill assigns a valuation rating of 1 / 10 to ARBUTUS BIOPHARMA CORP (ABUS). This can be considered as Overvalued.


Can you provide the profitability details for ARBUTUS BIOPHARMA CORP?

ARBUTUS BIOPHARMA CORP (ABUS) has a profitability rating of 1 / 10.


How financially healthy is ARBUTUS BIOPHARMA CORP?

The financial health rating of ARBUTUS BIOPHARMA CORP (ABUS) is 8 / 10.


What is the earnings growth outlook for ARBUTUS BIOPHARMA CORP?

The Earnings per Share (EPS) of ARBUTUS BIOPHARMA CORP (ABUS) is expected to grow by 48.31% in the next year.